160 related articles for article (PubMed ID: 20371447)
1. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.
Heider U; Rademacher J; Kaiser M; Kleeberg L; von Metzler I; Sezer O
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):134-7. PubMed ID: 20371447
[TBL] [Abstract][Full Text] [Related]
2. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.
Swaika A; Paulus A; Miller KC; Sher T; Almyroudis NG; Ball D; Wood M; Masood A; Lee K; Chanan-Khan AA
J Support Oncol; 2012; 10(4):155-9. PubMed ID: 22222250
[TBL] [Abstract][Full Text] [Related]
3. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
Pour L; Adam Z; Buresova L; Krejci M; Krivanova A; Sandecka V; Zahradova L; Buchler T; Vorlicek J; Hajek R
Clin Lymphoma Myeloma; 2009 Apr; 9(2):151-3. PubMed ID: 19406726
[TBL] [Abstract][Full Text] [Related]
4. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
5. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.
Vickrey E; Allen S; Mehta J; Singhal S
Cancer; 2009 Jan; 115(1):229-32. PubMed ID: 19090004
[TBL] [Abstract][Full Text] [Related]
6. Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Kim JW; Min CK; Mun YC; Park Y; Kim BS; Nam SH; Koh Y; Kwon JH; Choe PG; Park WB; Kim I
J Clin Virol; 2015 Dec; 73():64-69. PubMed ID: 26546878
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib and bilateral herpes zoster.
di Meo N; Bergamo S; Dondas A; Trevisan G
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
[TBL] [Abstract][Full Text] [Related]
8. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
[TBL] [Abstract][Full Text] [Related]
9. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.
Kim SJ; Kim K; Do YR; Bae SH; Yang DH; Lee JJ
Jpn J Clin Oncol; 2011 Mar; 41(3):353-7. PubMed ID: 20947927
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?
Dasanu CA; Alexandrescu DT
J Oncol Pharm Pract; 2010 Dec; 16(4):266-8. PubMed ID: 19965947
[TBL] [Abstract][Full Text] [Related]
11. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Chanan-Khan A; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Neuwirth R; Anderson KC; Richardson PG
J Clin Oncol; 2008 Oct; 26(29):4784-90. PubMed ID: 18711175
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.
Aoki T; Nishiyama T; Imahashi N; Kitamura K
Jpn J Clin Oncol; 2011 Jul; 41(7):876-81. PubMed ID: 21616919
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
Kim SJ; Kim K; Kim BS; Lee HJ; Kim H; Lee NR; Nam SH; Kwon JH; Kim HJ; Sohn SK; Won JH; Lee JH; Suh C; Yoon SS; Kim HJ; Kim I; Do YR; Lee WS; Joo YD; Shin HJ;
Clin Lymphoma Myeloma; 2008 Aug; 8(4):237-40. PubMed ID: 18765311
[TBL] [Abstract][Full Text] [Related]
14. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.
Minarik J; Pika T; Bacovsky J; Langova K; Scudla V
Br J Haematol; 2012 Oct; 159(1):111-3. PubMed ID: 22816982
[No Abstract] [Full Text] [Related]
15. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
[TBL] [Abstract][Full Text] [Related]
16. Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients.
van Besouw NM; Verjans GM; Zuijderwijk JM; Litjens NH; Osterhaus AD; Weimar W
J Med Virol; 2012 Dec; 84(12):2018-25. PubMed ID: 23080511
[TBL] [Abstract][Full Text] [Related]
17. Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus.
Park HB; Kim KC; Park JH; Kang TY; Lee HS; Kim TH; Jun JB; Bae SC; Yoo DH; Craft J; Jung S
J Rheumatol; 2004 Nov; 31(11):2151-5. PubMed ID: 15517626
[TBL] [Abstract][Full Text] [Related]
18. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
19. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
[TBL] [Abstract][Full Text] [Related]
20. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
